Skip to content
drillr.ai
Sign up

ESALY

Eisai Co.,Ltd.

医薬品 · 医薬品 · JP

Also listed · 4523.T →
—
Ask drillr

  • Nov 10, 2026, 09:03 UTC

    Eisai reported consolidated results for April–September 2026, with net profit up 22% year over year to ¥29.9 billion, revenue up 17% to ¥469.9 billion, and operating profit up 20% to ¥41.4 billion; Alzheimer’s and cancer drugs grew across all sales regions.

    Source:

  • Oct 28, 2026, 11:44 UTC

    Eisai reported preliminary revenue of ¥61.5 billion for lecanemab in April–September 2026, up 50% year over year, with growth mainly from U.S. sales.

    Source:

  • Sep 24, 2026, 21:58 UTC

    The FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.

    Source:

  • Sep 16, 2026, 07:44 UTC

    Eisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.

    Source:

  • Sep 15, 2026, 04:29 UTC

    ExaWizards announced that its AI interactive role-playing service ExaBase Roleplay has been adopted by Eisai.

    Source:

  • Sep 3, 2026, 04:00 UTC

    Eisai announced that China approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early Alzheimer's disease, enabling at-home administration.

    Source:

  • Aug 31, 2026, 23:30 UTC

    Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of Eisai's LEQEMBI (lecanemab) for early Alzheimer's disease.

    Source:

  • Aug 28, 2026, 00:18 UTC

    China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

    Source:

  • Aug 26, 2026, 09:31 UTC

    Japan's Ministry of Health, Labour and Welfare expert panel deliberated on approval of Eisai and Biogen's Alzheimer's drug Leqembi subcutaneous injection formulation, which would allow home administration.

    Source:

  • Aug 24, 2026, 12:00 UTC

    Eisai announced that the LEQEMBI IQLIK (lecanemab-irmb) autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer's disease.

    Source:

  • Aug 3, 2026, 15:55 UTC

    Eisai launched Leqembi (lecanemab) for early Alzheimer's disease in India, priced at ₹21,682 per vial.

    Source: